Skip to Content
Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

More News and Insights

  • The Old Dominion Group Has Been Acquired by Installed Building Products

    William Blair acted as the exclusive financial advisor to The Old Dominion Group in connection with its sale to Installed Building Products, Inc.

    Read more
  • WBIE and the Forces Reshaping International Equities

    On Bloomberg TV’s ETF IQ, Alaina Anderson discusses WBIE and opportunities across international equities, including AI, deglobalization, and reforms in Japan.

    Read more
  • Digital Printing Is Reshaping Flexible Packaging M&A

    Consumer trends, new technology are spurring transaction activity, particularly as legacy players look to add capabilities that provide more customization and serve smaller brands.

    Read more

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures